21056906[PMID] - PMC

1.

Figure 2. Comparisons between benign ovarian disease and healthy controls. From: Distinctive DNA-methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors.

A) Unsupervised principal component analysis; B) hierarchical clustering; C) Supervised linear discrimination analysis coupled with cross validation were used to determine informative genes; D) Sensitivity (Bold upper left) and specificity (Bold lower right).

Thomas E. Liggett, et al. Gynecol Oncol. ;120(1):113-120.

Citation Full text

2.

Figure 1. Comparisons between ovarian serous carcinoma and healthy controls. From: Distinctive DNA-methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors.

A) Unsupervised principal component analysis; B) hierarchical clustering; C) Supervised linear discrimination analysis coupled with cross validation were used to determine informative genes; D) Sensitivity (Bold upper left) and specificity (Bold lower right).

Thomas E. Liggett, et al. Gynecol Oncol. ;120(1):113-120.

Citation Full text

3.

Figure 3. Comparisons between benign ovarian disease and ovarian serous carcinoma. From: Distinctive DNA-methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors.

A) Unsupervised principal component analysis; B) hierarchical clustering; C) Supervised linear discrimination analysis coupled with cross validation were used to determine informative genes; D) Sensitivity (Bold upper left) and specificity (Bold lower right).

Thomas E. Liggett, et al. Gynecol Oncol. ;120(1):113-120.

Citation Full text

PMC

Result Filters

Article attributes

Text availability

Publication date

Custom date range

Research Funder

Additional filters

PMC Full-Text Search Results

Items: 3

Supplemental Content

Recent activity